T1	intervention 55 74	adjuvant clodronate
T3	total-participants 262 265	299
T4	eligibility 266 312	women with primary node positive breast cancer
T5	intervention-participants 363 366	149
T6	control 371 379	controls
T7	control-participants 381 384	150
T9	outcome 475 490	bone metastases
T10	iv-bin-abs 565 567	44
T11	iv-bin-percent 569 572	32%
T12	cv-bin-abs 578 580	42
T13	cv-bin-percent 582 585	29%
T14	outcome 616 653	frequency of non-skeletal recurrences
T15	iv-bin-abs 724 726	69
T16	iv-bin-percent 728 731	50%
T17	cv-bin-abs 763 765	51
T18	cv-bin-percent 767 770	36%
T19	outcome 783 819	Ten-year disease-free survival (DFS)
T20	iv-bin-percent 874 877	45%
T21	cv-bin-percent 882 885	58%
T22	outcome 938 974	oestrogen receptor negative patients
T23	iv-bin-percent 976 979	25%
T24	cv-bin-percent 984 987	58%
T25	outcome 1028 1044	overall survival
